Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary ...

Both trials are ongoing and will report on overall survival at a subsequent analysis. Topline results were announced from two phase 3 trials evaluating combination regimens containing belzutifan ...

Merck, known as MSD outside of the United States and Canada, and Eisai announced results from the phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients ...

Merck, known as MSD outside of the United States and Canada, and Eisai announced that the phase 3 LITESPARK-011 trial evaluating the dual oral regimen of Welireg (belzutifan), Merck’s first-in-class ...

Bavencio and Inlyta combination therapy demonstrated high six- and 12-month OS rates in advanced RCC patients in real-world settings. The AVION study confirmed the combination's safety, with 83.7% ...

(MENAFN- JCN NewsWire) WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With ...

Promoting to the front line two drugs normally used in rearguard action to treat advanced renal cell carcinoma (RCC) ― nivolumab (Opdivo) and cabozantinib (Cabometyx) ― doubled overall response rates ...

Source: Getty Images Avelumab plus axitinib did not improve overall survival in the overall population or in patients with PD-L1-positive disease. The median overall survival was 44.8 months in the ...